CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Researchers evaluated atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor. They found that dose intensification led to greater CDK4 inhibition and deeper antitumor responses. Combinatorial agents also further increased atirmociclib’s antitumor efficacy.